Why is cancer particularly 'damning' compared to other major chronic diseases?

Unlike cardiovascular and neurodegenerative diseases that increase exponentially with age and become dominant killers in later decades, cancer's mortality risk peaks in middle age (35-64). It consistently ranks among the top three causes of death across all adult age groups, making its impact widespread and unique.

How do different carcinogens influence cancer development at various ages?

Carcinogens like ultraviolet light cause cancers such as melanoma, which appears earlier in life. Smoking-related cancers (lung, head and neck, bladder) pick up in later decades due to prolonged exposure. Hormone-driven cancers like breast and prostate cancer also become more prevalent with age, often when hormone levels are lower, indicating tumor independence from growth factors.

What is the role of obesity in cancer development?

Obesity is the second most prevalent environmental trigger for cancer after smoking, linked to about 25-27 cancer types. The primary mechanisms are thought to be inflammation, insulin signaling, and IGF-1, which chronically drive growth factor pathways within cells, leading to genetic alterations and cancer.

What progress has been made in treating metastatic epithelial cancers since 1970?

From 1970 to 2000, there was virtually no progress in the 10-year survival for metastatic epithelial cancers. Today, with new therapies like PD-1 antibody-based immunotherapy (e.g., Keytruda) and molecularly targeted drugs, the 10-year survival rate has increased from near 0% to approximately 15-20%.

How does the immune system recognize and fight cancer?

The immune system identifies cancer cells by recognizing 'antigens'—fundamentally different proteins or mutated protein fragments presented on the cell surface. This immune surveillance system can eliminate nascent cancers, but cancer cells evolve mechanisms to hide or suppress immune responses.

What is the PD-1/PD-L1 mechanism in cancer immunity?

Cancer cells often express PD-L1 on their surface, which acts as a 'foot on the brake' for immune T-cells by binding to their PD-1 receptor, telling them to shut down. PD-1 antibody drugs (like Keytruda) block this interaction, unleashing the T-cells to attack the cancer. This mechanism has yielded a significant therapeutic benefit.

Why is it significant that 80% of epithelial tumors have novel neoantigens?

Neoantigens are unique mutated proteins in cancer cells that the immune system can recognize. The fact that most common cancers have these, and humans are born with T-cell receptors capable of recognizing them, indicates immense potential for immunotherapy. It suggests that by overcoming cancer's immune evasion, a large burden of cancer could be eliminated.

How does cell therapy, specifically TILs, work and what are its limitations?

Tumor Infiltrating Lymphocytes (TILs) are immune cells extracted from a patient's tumor, expanded in the lab to large numbers (e.g., 10^9), and reinfused. While capable of curing a minority of melanoma patients, it doesn't always work due to cancer's defense mechanisms, such as impeding direct killing at the tumor cell level, recruiting suppressive immune cells, and creating harsh microenvironments that hinder immune cell function.

What are the promising future directions in cancer therapy for the next five years?

Future focus includes metabolism-targeted therapies and epigenetic-targeted therapies, which aim to exploit cancer's unique metabolic disregulation and vulnerabilities, without harming healthy cells. These are expected to potentiate existing therapies like immunotherapy, potentially doubling long-term survival rates. Inducing mutagenesis, by using chemotherapy to push cancer cells over a genotoxic edge, is also being explored to enhance immune recognition.

Why are microscopic residual disease and early detection so crucial?

Microscopic residual disease (e.g., after surgery when no visible cancer remains) is much more curable with existing drugs than macroscopic, overt metastatic disease. This is because smaller cancer burdens have less clonal heterogeneity and are less capable of creating hostile microenvironments or evading immune responses. Early detection, therefore, pushes the 'starting point' to a much earlier stage where cancers are more vulnerable.

What is the current state of early cancer detection blood tests?

Commercial tests from companies like Grail, Exact (via Thrive), and Deli are available through physicians. These methods detect circulating tumor DNA (ctDNA) and methylation patterns. While promising for detecting a broad array of cancers earlier, they pose challenges for the medical community in managing positive results before a tumor is radiographically visible, potentially causing anxiety.

How can technology and expert opinion address disparities in cancer care?

The speaker suggests leveraging technology, specifically AI, to build databases of expert opinions for specific cancer cases. This could codify the decision-making process for typical cases, reserving human experts for rare or complex 'edge cases'. Such systems could make expert guidance more accessible and efficient, reducing healthcare costs and disparities.

Key Moments

267 ‒ The latest in cancer therapeutics, diagnostics, and early detection | Keith Flaherty, M.D.

Peter Attia MD

Science & Technology3 min read126 min video

Aug 21, 2023|41,963 views|782|62

Peter Attia MD Dr. Peter Attia Early Medical The Drive Podcast The Drive Longevity Zone 2

Save to Pod

Key Moments

TL;DR

Cancer diagnostics, therapeutics, and early detection are rapidly advancing, offering new hope.

Key Insights

Cancer's prevalence increases with age, but it remains a top cause of death across all age groups.

Metabolic dysregulation and inflammation, driven by factors like obesity, are significant contributors to cancer development.

Immunotherapy, particularly PD-1 inhibitors, has revolutionized cancer treatment by harnessing the immune system's power.

Tumor microenvironments present complex defense mechanisms that need to be overcome for effective treatment.

Blood-based diagnostics (ctDNA) show promise for early cancer detection and monitoring, though clinical management is still evolving.

Multimodality therapy, combining diverse approaches targeting cancer's complexity, is key to future success.

THE UNIQUE CHALLENGE OF CANCER

Cancer stands out among chronic diseases due to its consistent high ranking as a cause of death across all age demographics, unlike cardiovascular or neurodegenerative diseases which peak later in life. While pediatric cancers garner significant attention, and carcinogen-induced cancers like smoking-related ones rise in later decades, hormone-driven cancers such as breast and prostate cancers also show a strong age correlation. Understanding these patterns is crucial for tailoring screening and treatment strategies.

ADVANCES IN THERAPEUTICS: FROM TARGETED APPROACHES TO IMMUNOTHERAPY

The field has moved from a "one-size-fits-all" chemotherapy approach to highly sophisticated targeted therapies and immunotherapies. Molecular insights into genetic mutations have led to drugs that specifically attack cancer's drivers. Immunotherapy, particularly PD-1 antibodies, has been a game-changer, activating the patient's immune system to fight cancer. While these advances have significantly improved outcomes for some cancers, particularly those with numerous mutations like melanoma and lung cancer, others like pancreatic cancer remain challenging.

UNDERSTANDING AND COMBATTING CANCER'S DEFENSE MECHANISMS

Cancer cells are adept at developing resistance and evading the immune system. They can co-opt natural cellular processes, switch metabolic pathways, and create a hostile tumor microenvironment to suppress immune responses. Strategies like blocking immune checkpoints (e.g., PD-1/PD-L1) disrupt these defenses, but new approaches are needed to overcome more complex resistance mechanisms, recruit suppressive immune cells, and address metabolic vulnerabilities.

THE PROMISE OF EARLY DETECTION VIA LIQUID BIOPSIES

Significant strides are being made in early cancer detection, largely driven by advances in analyzing circulating tumor DNA (ctDNA) in blood samples. These 'liquid biopsies' can detect cancer at microscopic stages, potentially long before it's visible through traditional imaging. By analyzing mutations, fragment lengths, and methylation patterns, these tests can even help identify the cancer's origin, guiding targeted surveillance and treatment, though managing positive results and refining test sensitivity remains an ongoing challenge.

THE ROLE OF METABOLISM AND GENETIC INSTABILITY

Obesity, through chronic inflammation and altered growth factor signaling, is increasingly recognized as a major carcinogen, contributing to numerous cancer types. Furthermore, cancers often exploit altered metabolic pathways, like the Warburg effect, to fuel their rapid growth. Some cancers are also characterized by profound genetic instability, accumulating mutations to a degree that can either make them highly visible to the immune system or push them over the edge into cell death, a principle being explored for therapeutic advantage.

NAVIGATING COMPLEXITY: THE FUTURE OF CANCER CARE

The path forward involves a multifaceted approach, integrating diagnostics, targeted therapies, immunotherapy, and potentially metabolic or epigenetic modulators. While personalized cell therapies are advancing, challenges remain in specificity and scalability. The convergence of diagnostics and therapeutics, coupled with a deeper understanding of cancer's biology and the tumor microenvironment, is accelerating progress. Future breakthroughs will likely rely on combining therapies strategically, rather than relying on single mechanisms, to achieve durable responses and improve long-term survival rates.

Mentioned in This Episode

●Companies

●Organizations

●Books

●Concepts

●People Referenced

Common Questions

Compared to four years ago, diagnostic advancements, especially in understanding tumor genetics and identifying early indicators, have significantly accelerated. This convergence of diagnostics and therapeutics is now coming into view, promising substantially greater progress.